MK-2206 and standard neoadjuvant chemotherapy improves response in patients with human epidermal growth factor receptor 2–positive and/or hormone receptor–negative breast cancers in the I-SPY 2 trial

A. Jo Chien, Debasish Tripathy, Kathy S. Albain, W. Fraser Symmans, Hope S. Rugo, Michelle E. Melisko, Anne M. Wallace, Richard Schwab, Teresa Helsten, Andres Forero-Torres, Erica Stringer-Reasor, Erin D. Ellis, Henry G. Kaplan, Rita Nanda, Nora Jaskowiak, Rashmi Murthy, Constantine Godellas, Judy C. Boughey, Anthony D. Elias, Barbara B. HaleyKathleen Kemmer, Claudine Isaacs, Amy S. Clark, Julie E. Lang, Janice Lu, Larissa Korde, Kirsten K. Edmiston, Donald W. Northfelt, Rebecca K. Viscusi, Douglas Yee, Jane Perlmutter, Nola M. Hylton, Laura J. van’t Veer, Angela DeMichele, Amy Wilson, Garry Peterson, Meredith B. Buxton, Melissa Paoloni, Julia Clennell, Scott Berry, Jeffrey B. Matthews, Katherine Steeg, Ruby Singhrao, Gillian L. Hirst, Ashish Sanil, Christina Yau, Smita M. Asare, Donald A. Berry, Laura J. Esserman

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Fingerprint

Dive into the research topics of 'MK-2206 and standard neoadjuvant chemotherapy improves response in patients with human epidermal growth factor receptor 2–positive and/or hormone receptor–negative breast cancers in the I-SPY 2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences